Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4
NCT07522697
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Endometrial Cancer
Interventions
DRUG:
Inavolisib
Sponsor
National Cancer Institute, Naples